Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Method for treating a protozoal infection

a protozoal infection and protozoal technology, applied in the field of protozoal infection treatment, can solve the problems of increasing polypharmacy, increasing the risk factor for important morbidity and mortality, and virtually all medications have the potential to cause significant side effects

Inactive Publication Date: 2016-12-08
REID CHRISTOPHER BRIAN
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0006]Virtually all patients could benefit from novel, efficacious drug formulations. The present invention provides novel compositions and inexpensive drug formulations for preventing and / or treating various conditions, diseases, maladies and for improving health and well-being in general. The present invention also provides corresponding methods for producing such formulations and compositions.

Problems solved by technology

It has been taught that virtually all medications have the potential to cause significant side effects.
Accordingly, patients requiring treatment for multiple conditions frequently suffer from the cumulative side effects of multiple drugs, as well as adverse drug-drug interactions related to polypharmacy.
Polypharmacy is especially problematic in treatment of the elderly Hajjar et al., (2007) concluded that, “polypharmacy continues to increase and is a known risk factor for important morbidity and mortality.”
Often, polypharmacy results in reduced efficacy of one or more drugs.
In addition, a drug provided to treat one chronic condition may worsen another.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for treating a protozoal infection

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of Solid Lipid Nanoparticles

[0338]In one embodiment, the method chosen for the preparation of nanoparticles is an adaptation of the w / o / w double emulsion technique (Garcia-Fuentes et al 2003; Zhang et al 2006; Sarmento et. al., 2007). Approximately 200 mg of acetyl palmitate is dissolved in about 4 mL of dichloromethane 7 mg of zerumbone, a sesquiterpene and / or an equivalent effective amount of other agent(s), compound(s), or drug(s) of the present invention and glutathione) are dissolved in 0.5 mL of HCL 0.1 M. The drug solution is added to the lipid solution and then homogenized for 30 seconds in an ultra-turrax T25 (IKA-Labortechnik, Germany) or a similar apparatus. The primary emulsion is then poured into 25 mL of 2% poloxamer 407 solution and homogenized for another 30 seconds. The solvent is subsequently discarded and the emulsion is concentrated in a rotavapor until ˜10 ml_. Optionally, particle size can be analyzed using photon correlation spectroscopy (PCS); and...

example 2

Preparation of a Liposomal Formulation

[0340]A liposomal formulation comprising the agent(s), compound(s), and drug(s) of the present invention may be prepared according to Good Manufacturing Practices by the method of (Paul et al. (1997), previously described by Fessi at al. (1988). Briefly, an organic phase containing phospholipids and the drugs is introduced under magnetic stirring in an aqueous phase. The organic solvent is evaporated, and the liposomes obtained are filtered and lyophilized). Prior to administration, 50 mg of lyophilized liposomes are resuspended in sterile distilled water (20 ml), shaken for 3 min, and then diluted in 5% dextrose.

example 3

Preparation of a Tablet Formulation

[0341]Compressed tablets containing the pharmaceutical composition of the invention may be prepared by uniformly mixing the active ingredient(s) with a solid carrier to provide a mixture. The mixture is then compacted to the shape and size desired. Molded tablets maybe made in a suitable machine. To prepare a tablet formulation containing agents, compounds, or drugs of the present invention, the selected active components (e.g. Zerumbone and / or other agent(s), compound(s), or drug(s) of the present invention (80 g) and reduced glutathione (400 g)) may be mixed in the dry state for 10 minutes in a blade mixer. Likewise, a solution is prepared containing gelatin (16 g), dioctyl sodium sulphosuccinate (1 g), alcohol (57 g) and purified water (80 g). The solution is then wet mixed with the powders for 10 minutes using a slow speed. The wet mass is passed through a 1000 urn screen. Subsequently, the granules are dried in a fluidized bed at 60° C. for 30...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
body weightaaaaaaaaaa
conductivityaaaaaaaaaa
weightaaaaaaaaaa
Login to View More

Abstract

Patients inflicted with various clustering chronic diseases require treatment with multiple drugs having distinct mechanisms of action. Accordingly, patients with multiple conditions suffer from cumulative side effects of multiple drugs as well as drug-drug interactions. Embodiments, agents, compounds or drugs of the present invention, such as sesquiterpenes, e.g., Zerumbone, replace an equal or larger number of approved drugs during patient treatment. Examples of disorders prevented or ameliorated by administration of the formulations of this invention include but are not limited to inflammatory diseases that may be, oncological, genetic, ischemic, infectious, neurological, hematological, ophthalmological, rheumatoid, orthopedic, neurological, hematological, kidney, vascular, dermatological, gynecological, or obstetric. The present invention further relates to a method of identifying agents, compounds or drugs useful in preventing or treating CDCP related diseases and conditions as well as other disorders, diseases and conditions treatable or preventable by the same agents, compounds or drugs.

Description

[0001]Priority is claimed to U.S. provisional 61 / 404,571; 61 / 457,046; 61 / 634904 and a US provisional application submitted in February 2011.BACKGROUND OF THE INVENTION[0002]Strikingly a large number of serious chronic diseases such as cardiovascular disease, diabetes, obesity, hyperlipidemia, PCOS and hypertension) have been observed to cluster in patients. Such clustering can be identified in as many as one in five people on the planet and its prevalence increases with age. The problem is particularly acute in industrialized countries. Thus, chronic diseases such as cardiovascular disease, diabetes, obesity, hyperlipidemia, and hypertension, represent serious causes of polypharmacy, morbidity and reduced longevity. They also pose tremendous economic burdens on individuals, families and societies. Therefore, the identification of compositions and formulations capable of preventing or treating one or a combination of these disorders is desirable.[0003]In non-industrialized countries,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/496A61K45/06A61K31/4164
CPCA61K31/496A61K45/06A61K31/4164A61K38/1816A61K36/00A61K31/194A61K31/327A61K31/122A61K31/12A61K31/355A61K31/375A61K38/063Y02A50/30A61K2300/00
Inventor REID, CHRISTOPHER BRIAN
Owner REID CHRISTOPHER BRIAN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com